January 2018 Cancer Epidemiology Matters E-News

Cancer Epidemiology Matters E-News

January 2018

Research Highlights from EGRP Grantees

Each year, staff in the Epidemiology and Genomics Research Program (EGRP) nominate and vote for manuscripts published by EGRP grantees that are deemed to have the greatest potential scientific and/or public health impact. The following publications were chosen for inclusion in the 2017 Research Highlights:

Blood Cancer

Francis SS, Wallace AD, Wendt GA, Li L, Liu F, Riley LW, et al. In utero cytomegalovirus infection and development of childhood acute lymphoblastic leukemia. Blood. 2017 Mar 23;129(12):1680-1684.

Breast Cancer

Hoffman JD, Graff RE, Emami NC, Tai CG, Passarelli MN, Hu D, et al. Cis-eQTL-based trans-ethnic meta-analysis reveals novel genes associated with breast cancer risk. PLoS Genet. 2017 Mar 31;13(3):e1006690.

Chollet-Hinton L, Olshan AF, Nichols HB, Anders CK, Lund JL, Allott EH, et al. Biology and Etiology of Young-Onset Breast Cancers among Premenopausal African American Women: Results from the AMBER Consortium. Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1722-1729.

Clarke CA, Canchola AJ, Moy LM, Neuhausen SL, Chung NT, Lacey JV Jr, Bernstein L. Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study. Breast Cancer Res. 2017 May 1;19(1):52.

Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, et al. Association analysis identifies 65 new breast cancer risk loci. Nature. 2017 Nov 2;551(7678):92-94.

Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, et al. Identification of ten variants associated with risk of estrogen-receptor negative breast cancer. Nat Genet. 2017 Dec;49(12):1767-1778.

Lung Cancer

McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nat Genet. 2017 Jul;49(7):1126-1132.

Multiple Cancers

Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of Breast, Ovarian, Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017 Jun 20;317(23):2402-2416.

Lindström S, Finucane H, Bulik-Sullivan B, Schumacher FR, Amos CI, Hung RJ, et al. Quantifying the Genetic Correlation between Multiple Cancer Types. Cancer Epidemiol Biomarkers Prev. 2017 Sep;26(9):1427-1435.

Survivorship

Bhakta N, Liu Q, Ness KK, Baassiri M, Eissa H, Yeo F, et al. The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet. 2017 Dec 9;390(10112):2569-2582.

Research Highlights nominees are drawn from an annual compilation of grantees' manuscripts. Please see the article at the bottom of this newsletter highlighting additional reasons to alert your EGRP Program Director of publications supported by NCI funds.



Quick Tip on Revisions for Current Grantees

Grantees with at least one year remaining on their grant who want to expand their project's scope may request a revision (also known as a competitive revision, competing revision, or a competitive supplement). Please note that a revision is neither an administrative supplement (a noncompeting award that provides additional funding to a currently funded grant to meet increased costs that are within the scope of the approved project) nor an application resubmission (an unfunded application that has been modified following initial review and resubmitted for new consideration). Any grantee interested in a revision must submit an application, which must undergo peer review and be selected for funding.

Investigators may apply for revisions either through a revision-specific Funding Opportunity Announcement (FOA), or to the FOA to which the parent grant was submitted (or a reissuance of that FOA), as long as that FOA allows revision applications. Revisions may not extend beyond that grant's project period. Also, revisions do not restore funds that were part of standard grant reductions.

Below are some examples of NCI FOAs accepting revision applications.

Revision Applications to National Cancer Institute (NCI)-supported Awards to Include Research on the NCI's Provocative Questions
Applications due: June 28, 2018; October 30, 2018
Expiration date: October 31, 2018

To learn more about NCI's Provocative Questions awards, consider attending this Pre-Application Webinar on NCI's Provocative Questions Relevant to Population ScientistsExternal Web Site Policy on February 15, 2018, 2:00 - 3:00 p.m. ET.

Revisions for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research
Applications Due: February 28, 2018; May 29, 2018; September 28, 2018
Expiration Date: September 29, 2018

View more information about revisions to an existing grant.



Publishing Soon? Let Us Know!

Each year, EGRP provides funding for hundreds of research grants, which results in numerous publications. EGRP would like to help you and your institution get the word out about your work; having advance notice of publication is important for planning purposes. There are several reasons sending a quick email to your EGRP Program Director (PD)--when your research is accepted for publication--is a good idea:

If a study receives a great deal of attention in mass media, the media, patients, or advocates may contact NCI with questions. In these cases, it is helpful to have advance notice of publication so that NCI staff have time to become familiar with the study results and can be prepared to answer questions from the public.

When NCI has advance notice of publications, it may want to highlight research from its grantees via blog posts, social media, and coordination with news media outlets. Large-scale publicity efforts, however, require time to plan, so letting your PD know about any potentially newsworthy research results when they are accepted for publication is essential.

EGRP may also use its @NCIEpi Twitter accountExternal Web Site Policy to spread the word about NCI-funded epidemiology and genomics research. Approximately 5,700 Twitter accounts receive updates from @NCIEpi, including scientists, government agencies, research organizations, students, advocates, and other NIH-affiliated accounts.

Whether you are a new EGRP grantee or a seasoned investigator, it pays to let us know about your EGRP-funded research publications. So next time a journal article of yours is accepted, be sure to email your EGRP PD with the news!

Funding Opportunities

  • Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01)
  • Partnership for Aging and Cancer Research (U01)
  • PHS 2018-02 Omnibus Solicitation of the NIH for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44], Parent SBIR [R43/R44])
  • PHS 2018-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42], Parent STTR [R41/R42])
  • Research Supplements to Promote Diversity in Health-Related Research (Admin Supp)
  • New Epidemiology Cohort Studies in Heart, Lung, Blood, and Sleep Diseases and Disorders (U01 [NCI is not participating in this FOA])
  • International Research Scientist Development Award (K01, K01)
  • Early-life Factors and Cancer Development Later in Life (R03, R21, R01)
  • NIH Research Project Grant (Parent R01, Parent R01 [NCI is not participating in this FOA])
  • Cancer Prevention and Control Clinical Trials Grant Program (R01)
  • Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp)
  • Research Supplements to Promote Diversity in Health-Related Research (Admin Supp)
  • Research Supplements to Promote Re-Entry into Biomedical and Behavioral Research Careers (Admin Supp)

Return to Top